Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Manganese dioxide nanometer adjuvant and preparation method and application thereof

A technology of manganese dioxide and manganese chloride, which is applied in the field of biomedicine, can solve problems such as the difficulty in inducing cellular immune responses, the difficulty in effectively improving antigen immunogenicity, inflammation and allergic reactions, etc., so as to improve immune stimulation and immune protection function, the effect of improving immunogenicity

Pending Publication Date: 2017-12-12
SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antigen-carrying capacity of these materials is not ideal, and it is difficult to effectively improve the immunogenicity of antigens
[0004] As the only clinically approved vaccine adjuvant, aluminum adjuvant can effectively promote antigen-induced humoral immune response, but it is difficult to induce cellular immune response, which is obviously not good for clearing endogenous pathogens such as HIV and tumor cells
At the same time, aluminum adjuvants have certain side effects, which can cause inflammation and allergic reactions at the injection site

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Manganese dioxide nanometer adjuvant and preparation method and application thereof
  • Manganese dioxide nanometer adjuvant and preparation method and application thereof
  • Manganese dioxide nanometer adjuvant and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0055] The present invention also provides a kind of preparation method of manganese dioxide nanometer material, comprises the following steps:

[0056] A) After mixing the manganese chloride solution and the loaded substance solution, incubate (that is, stand at room temperature) to obtain the complex;

[0057] The loaded substances include CpG oligonucleotides and / or antigens; the antigens include protein antigens and / or polypeptide antigens;

[0058] B) reacting the complex obtained in the above steps with sodium hydroxide solution to obtain manganese dioxide nanomaterials.

[0059] The preferred principles or specific preferred schemes such as the nature, structure, and ratio of the raw materials or products in the preparation method of the present invention are consistent with the aforementioned preferred principles and specific preferred schemes of the manganese dioxide nanomaterials, and will not be repeated here.

[0060] In the present invention, the manganese chlori...

Embodiment 1

[0087] Manganese dioxide-antigen (MnO 2 -OVA) and manganese dioxide-CpG (MnO 2 -CpG) nano adjuvants

[0088] First, 0.5 mL of OVA solution (45 μM) or CpG solution (16 μM) was added dropwise to 1 mL of manganese chloride solution (MnCl 2 , 1mM), incubate at room temperature for 15-30 minutes; then, add 12 μL of sodium hydroxide solution (1M) to the above solution, and continue the reaction for 1.5 hours; finally, place the reaction solution in a dialysis bag (molecular weight cut-off 3500Da) Dialyze for 4 to 6 hours, and replace the fresh dialysate (deionized water) every hour to obtain yellow-brown MnO 2 -OVA and MnO 2 - CpG nanoadjuvants.

[0089] Utilize inductively coupled plasma spectrometry (ICP-AES) to the MnO prepared by the embodiment of the present invention 1 2 -OVA and MnO 2 -MnO in CpG nano adjuvants 2 The concentration of MnO in the two nano-adjuvants was detected, and the results showed that 2 The concentration is 0.53mM, which is about 80% MnCl 2 The fi...

Embodiment 2

[0095] Acid Responsiveness and Magnetic Resonance Imaging of Manganese Dioxide Nanoadjuvants

[0096] MnO 2 -OVA and MnO 2 - The CpG nano-adjuvant was diluted 5 times with phosphate buffer (pH7.4, pH5.0) with different pH conditions, incubated at room temperature, and the color change of the solution was observed. At the same time, the above four solutions were respectively gradiently diluted, and then the T1-enhanced magnetic resonance signal (R1) was detected by a magnetic resonance imager.

[0097] see image 3 , image 3 For the MnO obtained in Example 2 of the present invention 2 -OVA nanoparticles solution and MnO 2 - Acid responsiveness and magnetic resonance imaging evaluation results of CpG nanoparticle solutions.

[0098] The result is as image 3 Shown, MnO 2 -OVA and MnO 2 -CpG changed from yellow-brown to a colorless solution in an acidic environment, indicating that the manganese dioxide nano-adjuvant had been dissolved into manganese ions. At the same ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides a manganese dioxide nanometer material. The manganese dioxide nanometer material comprises manganese dioxide nanoparticles and carried matter, wherein the carried matter is compounded onto the surface of the manganese dioxide nanoparticle; the carried matter comprises oligonucleotide CpG and / or antigen; the antigen comprises protein antigen and / or polypeptide antigen. The provided manganese dioxide nanometer material has the advantages that the immunostimulation function of an immunologic adjuvant CpG is greatly improved, the immunity protection function of vaccine is improved, and the inherent defect of effective improving of immune reaction by a large amount of CpG because the oligonucleotide CpG is used as an immunologic stimulant and cannot easily enter the body lymph glands is solved; the manganese dioxide nanometer material is used as a vaccine adjuvant, and can carry the antigen, especially the protein antigen, so that the intake on the antigen by the immune cells in the lymph glands is effectively improved, and the immunogenicity of the antigen is improved; the nanometer adjuvant can be biologically degraded, and can be gradually degraded into manganese ions (Mn<2+>) under the weak acid environment, such as lysosome, and the manganese ions are finally discharged out of the human body.

Description

technical field [0001] The present invention relates to the field of biomedical technology and vaccine technology, in particular to a manganese dioxide nano material and its preparation method and application, in particular to a manganese dioxide nano adjuvant and its preparation method and application. Background technique [0002] Vaccines are immune preparations made from pathogenic microorganisms (such as bacteria, rickettsia, viruses, etc.) and their metabolites through artificial attenuation, inactivation, or genetic engineering to prevent infectious diseases. Vaccines retain the properties of pathogens that stimulate the body's immune system. When the animal body comes into contact with this harmless pathogen, the immune system will produce certain protective substances, such as cytokines, active physiological substances, special antibodies, etc.; Follow its original memory to create more protective substances to prevent the damage of pathogens. Since its inception,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39
CPCA61K39/39A61K2039/55505A61K2039/55561Y02A50/30
Inventor 刘庄许利耕陈倩彭睿
Owner SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com